14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.72 $7.24 Wednesday, 24th Apr 2024 AFMD stock ended at $4.88. This is 8.79% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 11.72% from a day low at $4.87 to a day high of $5.44.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Jun 07, 2021 $81.60 $85.30 $81.10 $84.40 125 831
Jun 04, 2021 $82.40 $83.00 $80.20 $81.00 91 124
Jun 03, 2021 $83.90 $83.90 $79.70 $82.20 177 365
Jun 02, 2021 $83.00 $85.65 $82.40 $84.20 118 353
Jun 01, 2021 $89.20 $90.30 $82.10 $83.70 216 829
May 28, 2021 $90.80 $92.30 $88.40 $88.70 76 804
May 27, 2021 $89.00 $90.90 $86.60 $90.50 86 562
May 26, 2021 $87.70 $89.25 $86.40 $88.20 221 668
May 25, 2021 $90.60 $91.20 $86.90 $87.00 151 248
May 24, 2021 $93.70 $94.45 $89.20 $90.40 136 584
May 21, 2021 $96.70 $97.00 $91.70 $92.00 111 127
May 20, 2021 $94.60 $95.10 $92.70 $94.60 63 321
May 19, 2021 $94.80 $96.40 $91.90 $95.00 94 074
May 18, 2021 $94.50 $98.20 $93.12 $96.90 173 385
May 17, 2021 $86.20 $95.00 $86.00 $93.80 125 467
May 14, 2021 $88.10 $93.60 $87.90 $88.00 240 921
May 13, 2021 $92.60 $93.80 $87.20 $88.60 397 968
May 12, 2021 $91.30 $93.80 $90.70 $91.40 170 734
May 11, 2021 $89.50 $94.25 $88.80 $93.80 191 057
May 10, 2021 $97.00 $97.00 $91.50 $93.80 156 026
May 07, 2021 $97.50 $101.10 $96.97 $98.10 172 023
May 06, 2021 $102.90 $103.20 $93.30 $97.00 272 504
May 05, 2021 $105.80 $106.30 $101.70 $103.20 131 654
May 04, 2021 $107.60 $108.00 $103.60 $105.60 137 499
May 03, 2021 $107.00 $112.20 $106.60 $109.20 145 651
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT